Vontobel Holding Ltd. Acquires 552 Shares of Solventum Co. (NYSE:SOLV)

Vontobel Holding Ltd. boosted its holdings in Solventum Co. (NYSE:SOLV) by 11.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,292 shares of the company’s stock after purchasing an additional 552 shares during the quarter. Vontobel Holding Ltd.’s holdings in Solventum were worth $350,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in SOLV. Hotchkis & Wiley Capital Management LLC bought a new position in Solventum in the 3rd quarter worth approximately $125,488,000. Trian Fund Management L.P. boosted its stake in Solventum by 32.9% in the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock worth $496,842,000 after purchasing an additional 1,765,676 shares during the period. Point72 Asset Management L.P. bought a new position in Solventum in the 3rd quarter worth approximately $50,948,000. Nordea Investment Management AB raised its holdings in shares of Solventum by 189.5% during the 4th quarter. Nordea Investment Management AB now owns 659,887 shares of the company’s stock worth $43,902,000 after acquiring an additional 431,986 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Solventum by 4,765.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 319,628 shares of the company’s stock worth $22,284,000 after acquiring an additional 313,058 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Mizuho assumed coverage on Solventum in a report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price objective on the stock. Piper Sandler upped their price objective on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Finally, Morgan Stanley upped their price objective on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, Solventum has an average rating of “Hold” and an average target price of $68.29.

Solventum Stock Performance

NYSE:SOLV opened at $74.44 on Friday. The stock’s fifty day moving average is $71.07 and its 200 day moving average is $68.95. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $96.05. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.